# SIBN earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SIBN) · [Earnings tab](https://www.lopjlb.com/stock/SIBN?tab=earnings)

Updated: 2026-08-03T08:40:37

Quarters analyzed: 6

## Cross-quarter narrative

Across six quarters, SI-BONE has demonstrated consistent top-line growth, with revenue rising from $40M in 2024 Q2 to $48.7M in 2025 Q3, representing 20-26% year-over-year increases each quarter. Profitability has markedly improved: adjusted EBITDA loss narrowed 43% YoY in 2024 Q2, reached near-breakeven in Q3, turned positive in Q4, and sustained positive adj. EBITDA through 2025, with operating cash flow breakeven achieved ahead of schedule in 2025 Q2. The physician base expanded from >1,150 to 1,400+ active physicians, and procedure volumes grew 25% in 2025 Q2. Product pipeline execution accelerated: Gran

## Latest CallCard · Q3

SI-BONE delivered 21% revenue growth to $48.7M, achieved positive adj. EBITDA and operating cash flow, raised 2025 guidance, and advances two 2026 product launches with interventional expansion.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize strong growth, profitability milesto

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q3:** SI-BONE delivered 21% revenue growth to $48.7M, achieved positive adj. EBITDA and operating cash flow, raised 2025 guidance, and advances two 2026 product launches with interventional expansion.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize strong growth, profitability milesto
- **2025 Q2:** SI-BONE delivered 22% worldwide revenue growth, 25% procedure volume growth, and achieved cash flow breakeven ahead of schedule while launching iFuse TORQ in Europe and advancing pipeline with two breakthrough devices.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted record physician
- **2025 Q1:** SI-BONE Q1 2025: $47.3M revenue (+25%), positive adj EBITDA, raised FY revenue guidance to $193.5-197.5M, gross margin 79.7%, record 1,400+ active physicians, new product launches driving broad-based growth.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management expressed strong confidence in growth t
- **2024 Q4:** SI‑BONE posted record $49 M Q4 revenue (+26%) and positive adjusted EBITDA, reaffirmed 2025 guidance of 16‑17% growth while highlighting strong physician demand, new product momentum and ongoing reimbursement and legal risks.
- **2024 Q3:** SI-BONE delivered record Q3 revenue of $40.3M (+19%), nearing adj. EBITDA breakeven, launched TNT breakthrough device, secured TPT for Granite, raised 2024 guidance to $165-166M.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management highlighted record revenue, near EBITDA breakeven, multiple product 
- **2024 Q2:** SI-BONE delivered record $40M revenue (+20%), >1,150 active physicians (+23%), and 43% adjusted EBITDA improvement; expects Q4 EBITDA breakeven and accelerating H2 growth driven by Granite 9.5, interventional spine expansion, and Q4 trauma product launch. Cash $151M supports self-funding. STACI publ

## Guidance path

2024 Q2:maintained → 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SIBN`